Log in
NASDAQ:RNA

Prosensa Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$29.87
-4.08 (-12.02 %)
(As of 09/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$29.76
Now: $29.87
$35.45
50-Day Range N/A
52-Week Range
$4.12
Now: $29.87
$22.80
Volume170,999 shs
Average Volume149,633 shs
Market Capitalization$1.12 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company's primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. The Company's clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company's platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.
Read More
Prosensa logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RNA
CUSIPN/A
Phone858-401-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$1.12 billion
Next Earnings Date11/9/2020 (Estimated)
OptionableNot Optionable

Receive RNA News and Ratings via Email

Sign-up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Prosensa (NASDAQ:RNA) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Prosensa?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prosensa in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Prosensa
.

When is Prosensa's next earnings date?

Prosensa is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for Prosensa
.

How were Prosensa's earnings last quarter?

Prosensa Holding NV (NASDAQ:RNA) released its quarterly earnings results on Monday, August, 10th. The biotechnology company reported ($1.23) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.99. The biotechnology company earned $1.54 million during the quarter.
View Prosensa's earnings history
.

What price target have analysts set for RNA?

4 analysts have issued 12-month price objectives for Prosensa's stock. Their forecasts range from $34.00 to $60.00. On average, they anticipate Prosensa's share price to reach $43.33 in the next year. This suggests a possible upside of 45.1% from the stock's current price.
View analysts' price targets for Prosensa
.

Who are some of Prosensa's key competitors?

What other stocks do shareholders of Prosensa own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prosensa investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), Ibio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

When did Prosensa IPO?

(RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO.

What is Prosensa's stock symbol?

Prosensa trades on the NASDAQ under the ticker symbol "RNA."

When does Prosensa's lock-up period expire?

Prosensa's lock-up period expires on Wednesday, December 9th. Prosensa had issued 14,400,000 shares in its public offering on June 12th. The total size of the offering was $259,200,000 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

What is Prosensa's stock price today?

One share of RNA stock can currently be purchased for approximately $29.87.

How big of a company is Prosensa?

Prosensa has a market capitalization of $1.12 billion.

What is Prosensa's official website?

The official website for Prosensa is www.aviditybiosciences.com.

How can I contact Prosensa?

Prosensa's mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The biotechnology company can be reached via phone at 858-401-7900 or via email at [email protected]

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.